Romania: The Pharma Sector. A Recurring Star In The Spotlight Of The Procedures Instrumented By The Competition Authority

Last Updated: 9 October 2017
Article by Andreea Oprișan

In one way or another, the pharma sector continues to be under the scrutiny of the Romanian Competition Council's (RCC's).

Relatively recently, the RCC released its final report on the second sector inquiry (Second Sector Report) into the Romanian pharma market, while other investigations on the market relating to potential breaches of competition law pursuant to the implementation of limited distribution systems or direct-to pharmacy (DTP) systems are still pending (according to publicly available data). Based on the available public information, at least two separate investigations into various DTP systems implemented by suppliers of pharmaceutical products are underway.

" The star topics of the Second Sector Report are (i) the marketing expenses and pricing of generic versus original drugs; and (ii) the limited distribution/DTP systems.

The level of marketing expenses borne by the suppliers of original drugs, especially upon patent expiry, is a major concern for the authority, as it raises barriers to entry and/or expansion for competing generic drugs.

The RCC observed that marketing efforts have a direct impact on market share, and therefore protection measures must be taken.

Unlike other competition authorities, for instance the competition authority of the United Kingdom1, the RCC appears to indicate that it will not intervene where a regulatory authority should act.

Therefore, on the topic of marketing expenses and cost-efficient drugs, the RCC makes recommendations or proposals de lege ferenda to other state authorities, rather than identifying competition policy trends.

Obviously, this does not mean that the authority will not intervene where it identifies a potential breach of competition law.

The main recommendations related to marketing efforts for medicines and promoting cost-efficient  drugs include:

  • Equivalent pricing for innovative and generic drugs based on the International Non-proprietary Name. However, the recommendation is subject to a prior impact assessment study so as to avoid the policy triggering market exits;
  • Eliminating from the regulated price list products that are not put on the market in sufficient quantities within a certain reference period (normally 6 months), but are kept on the list with the sole purpose of setting a reference price;
  • Levelling the distribution and pharmacy mark-ups by reference to a similar system to a service tax;
  • Legal measures to limit maximum discount levels, especially if such discounts are not passed on to patients. Nevertheless, the authority emphasises that the measure should not trigger minimum price thresholds banned under competition rules;
  • Close monitoring of prescription patterns (innovative versus generics) by the National House of Health Insurance and potential implementation of the target threshold for the prescription of generics. Also, the sums spent on advertising drugs should be closely monitored and corresponding measures implemented according to the results of the monitoring;
  • Information programmes for doctors, pharmacies and patients, as well as a system of financial incentives for doctors not exceeding a certain monthly budget in their prescription activities;
  • It is also suggested that lower claw-back taxes for generics may help support the market entry and presence on the market of cost-efficient products.

" Another hot topic of the RCC's assessment relates to the different measures undertaken by pharmaceutical companies to ensure rapid and efficient access to products on the market.

The RCC acknowledges in the Second Sector Report that shortages of medicine may occur on the market due to either insufficient product volumes put on the market or parallel trade. However, the proposed solution to such shortages does not rest on a particular distribution system, but rather to strong legal provisions related to the fulfilment of public service obligations allowing the regulatory authority to (i) verify/monitor the manner in which companies in the production-distribution-retail chain fulfil their public service obligations; as well as (ii) to apply severe fines if such obligations are not observed.

In terms of the various distribution systems aimed at ensuring rapid and efficient access to products on the market, the authority does not discriminate between (i) the traditional distribution system (multiple distributors); (ii) the limited distribution system (e.g., 3 distributors); and (iii) the DTP system, but emphasised that the latter two systems might raise competition law compatibility issues in the case of dominant companies, in particular, if benefits are not passed on to patients2.

" In any case, out of all the assessment topics put forward by the RCC in the Second Sector Report, the undisputable front stage star is the DTP system.

The RCC is currently investigating various DTP systems implemented on the Romanian market. Based on public information, one of the investigations is currently exploring the commitments option, meaning that the investigation will be closed with no consequences subject to a set of behavioural rules being adopted by the party under investigation for a determined period3.

Even though the investigations are still ongoing, the Second Sector Report includes some important conclusions on the DTP system going forward:

  • The DTP system is not illegal per se, but may be anticompetitive if implemented by a dominant company;
  • The DTP system is normally based on services provided by a logistics agent. It is recommended that the selection procedure of the logistics agent is based on competitive and transparency principles;
  • The switch from traditional distribution to the DTP system should allow distributors sufficient time to adapt and develop new strategies. However, the applicable reasonable time-frame for this is still to be determined. In any case, it should be adjusted depending on the product concerned; and
  • The DTP system should be based on objective needs and should lead to efficiencies such as: (i) ensuring product availability; (ii) passing benefits on to the patients and pharmacies (both in terms of financial benefits and the service provided, including timely delivery and ease of order); and (iii) reducing the risk of counterfeit products coming onto the market.

Also, the DTP system should not represent a means to implement anticompetitive practices such as the restriction of parallel trade.

The final conclusions on the DTP systems will be clearer once the RCC issues its final position on the ongoing investigations into DTP systems already implemented by some pharmaceutical companies in Romania (e.g., GSK4).

In any case, it is obvious that the implementation of a DTP system would require careful consideration, in particular if this system were considered for dominant products. This should not represent an absolute barrier to the implementation of a DTP system, but it would require extensive efforts even from the moment the DTP system were merely on the drawing board. Also, the system may require careful assessment not only from competition-law perspective, but also from regulatory perspective.

Even though the pharma sector presents particularities that are not applicable to other industries (e.g., FMCG), for instance, given the compensation of certain drugs by the National House of Health Insurance and the role of the prescribing physician in patient care and acquisition trends, the concepts developed by the RCC relating to the DTP system might be considered by dominant companies in other industries as best practices, were a similar system used in their sector of activity.

Posing fewer risks of negatively impacting the competitive environment than the DTP system, the limited distribution system seems to be regarded with less concern by the authority, without being granted an absolute green light.

The assessment undertaken by the authority showed both positive and negative sides. The positive effects of a limited distribution system are:

  • Enhanced service level and collaboration between supplier and distributors. Distributors being selected following an objective process would represent an important step towards such results;
  • Enhanced product availability; and
  • Support in the fight against counterfeit products. Nevertheless, the limited distribution system also has its drawbacks:
  • Disadvantages (e.g., in delivery and commercial terms) for independent pharmacies as distributors tend to primarily supply their vertically integrated pharmacy chains;
  • Potential disadvantages for small or regional wholesale distributors; and
  • Potential risks of anticompetitive behaviour.

Even though the approach appears to be more relaxed in the case of the limited distribution system, upon the implementation of this model, especially in the case of dominant products, it could be sensible to adjust some of the rules developed by the RCC for the DTP system in order to mitigate potential competition law risks.

To conclude, the Second Sector Report, although it does not take the form of best practice guidelines from the authority, represents a useful assessment tool for companies implementing a DTP or limited distribution system. Its general conclusions may also be relevant to other industries.

In any case, it will be interesting to follow the final RCC conclusions from its ongoing investigations into the DTP system, as they will be of the utmost importance in fine-tuning the legal approach.


1. The competition authority in the United Kingdom investigated cases and applied sanctions against pharmaceutical companies relating to excessive prices in the context of generics entry (e.g., the Pfizer/Flynn and Actavis cases).

2. Under Romanian Competition Law No. 21/1996 there is a rebuttable presumption of dominance above a 40% market share threshold.

3. The RCC submitted for public consultation the commitments proposed by GlaxoSmithKline in connection with its DTP system in Romania. Public information may be found at:

4. Commitments proposed by GSK on its DTP system are publicly available at

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions